We demonstrate that an SGLT2 inhibitor significantly suppresses NLRP3 inflammasome activation and subsequent secretion of IL-1β in human macrophages, via increased serum BHB levels and decreased serum levels of insulin, among patients with T2D and CVD, regardless of glycemic control. The gene discussed is IL1B; the disease is type 2 diabetes mellitus.